Name: Jean-Claude “JC” Kyrillos

New title: Chief operating officer, Tandem Diabetes Care

Previous title: President of diagnostics and digital solutions, Envista Holdings

Tandem Diabetes Care has appointed Jean-Claude Kyrillos as chief operating officer, the company said Thursday.

The appointment gives Kyrillos a leading role in work to expand the insulin delivery company’s global operations and achieve profitable growth. Kyrillos last worked at Envista, a dental care company that was spun off from Danaher in 2019, and held positions at Qualcomm’s healthcare unit, Becton Dickinson and Resmed earlier in his career. 

Tandem CEO John Sheridan said Kyrillos “brings deep experience in healthcare and a great balance of technical, operational, and leadership skills from multiple roles in large and small medical technology companies” in a statement about the new hire. 

The appointment, which is effective June 21, fills a vacancy created by the exit of David Berger at the end of 2023. Berger, who spent 10 years at Tandem, led the company’s clinical, quality and regulatory functions but stepped down after less than two years as chief operating officer. Tandem entered into a transition and consulting pact to keep Berger involved until June 30.

Kyrillos has joined Tandem almost one year after leaving Envista. The Danaher spinoff and Kyrillos “mutually agreed” to terminate his employment last year. 

Tandem disclosed the appointment of Kyrillos days after issuing a statement about changes to its development and commercialization agreements with Dexcom. The deals, which were struck in 2020, cover the integration of Tandem’s insulin pumps with Dexcom’s continuous glucose monitor (CGM) devices.

The restated agreements incorporate the integration of Tandem’s Sigi insulin pump with Dexcom’s G7 CGM device and extend the terms for five years.